Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary

Guidelines and Expert Consensus documents aim to present management and recommendations based on all of the relevant evidence on a particular subject in order to help physicians to select the best possible management strategies for the individual patient, suffering from a specific condition, taking into account not only the impact on outcome, but also the risk benefit ratio of a particular diagnostic or therapeutic procedure. The ESC recommendations for guidelines production can be found on the ESC website†. In brief, the ESC appoints experts in the field to carry out a comprehensive and critical evaluation of the use of diagnostic and therapeutic procedures and to assess the risk–benefit ratio of the therapies recommended for management and/or prevention of a given condition. The strength of evidence for or against particular procedures or treatments is weighed according to predefined scales for grading recommendations and levels of evidence, as outlined below. Once the document has been finalized and approved by all the experts involved in the Task Force, it is submitted to outside specialists for review. If necessary, the document is revised once more to be finally approved by the Committee for Practice Guidelines and selected members of the Board of the ESC. The ESC Committee for Practice Guidelines ( CPG ) supervises and coordinates the preparation of new Guidelines and Expert Consensus Documents produced by Task Forces, expert groups, or consensus panels. The chosen experts in these writing panels are asked to provide disclosure statements of all relationships they may have, which might be perceived as real or potential conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. The Committee is also responsible for the endorsement of these Guidelines and Expert Consensus Documents or statements. | Classes of recommendations | |:-------------------------- | ------------------------------------------------------------------------------------------------------------------------ | | Class I | Evidence and/or general agreement that a given diagnostic procedure/treatment is beneficial, useful, and effective | | Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the treatment or procedure | |  Class IIa | Weight of evidence/opinion is in favour of usefulness/efficacy | |  Class IIb | Usefulness/efficacy is less well established by evidence/opinion | | Class III | Evidence or general agreement that the treatment or procedure is not useful/effective and, in some cases, may be harmful | Diabetes and cardiovascular diseases (CVD) often appear …

Peter Lindgren | Ilse Vanhorebeek | Silvia G Priori | Bengt Jönsson | Marco Stramba-Badiale | John Camm | Eberhard Standl | John Betteridge | Erland Erdmann | Michel Bertrand | Qing Qiao | Jaakko Tuomilehto | Massimo Volpe | Lars Rydén | M. Laakso | G. Van den Berghe | J. Camm | K. Dickstein | S. Priori | G. V. Berghe | J. Tuomilehto | L. Rydén | J. Tamargo | J. Blanc | A. Budaj | Verónica Dean | J. Deckers | J. Lekakis | K. Mcgregor | M. Metra | J. Morais | A. Osterspey | J. Zamorano | K. Pyörälä | K. Malmberg | E. Erdmann | E. Ferrannini | M. Bertrand | M. Volpe | B. Jönsson | M. de Boer | D. Wood | I. Vanhorebeek | B. Charbonnel | A. Flyvbjerg | I. Raz | G. Schernthaner | K. Parhofer | E. Standl | F. Cosentino | M. Stramba-Badiale | Q. Qiao | H. Gohlke | J. Betteridge | J. Ostergren | Jan Ostergren | Greet Van den Berghe | John Lekakis | Jaap W Deckers | Ele Ferrannini | Jean-Jacques Blanc | João Morais | Andrzej Budaj | Jaap Deckers | Keith McGregor | Markku Laakso | Itamar Raz | José Luis Zamorano | Allan Flyvbjerg | Juan Tamargo | Menko-Jan de Boer | Guntram Schernthaner | Kalevi Pyörälä | David Wood | Veronica Dean | Kenneth Dickstein | Francesco Cosentino | Małgorzata Bartnik | Klas Malmberg | Marco Metra | Ady Osterspey | I. Thrainsdottir | Klaus Parhofer | Helmut Gohlke | Inga Thrainsdottir | Bernard Charbonnel | Jose Ramon Gonzalez Juanatey | Pedro Filipe Monteiro | Silvia Priori | P. Lindgren | M. Bartnik | J. R. Juanatey | I. Graham | P. Monteiro | Ian Graham | K. Pyörälä | J. Juanatey | V. Dean

[1]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[2]  M. Shipley,et al.  CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.

[3]  R. Rutherford,et al.  Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.

[4]  Erzo F. P. Luttmer,et al.  The Cost of Diabetes , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[5]  J. Deckers,et al.  Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. , 1995, British heart journal.

[6]  J. Halperin,et al.  Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). , 1999, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  M. Schroll,et al.  Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. , 1995, Stroke.

[8]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[9]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[10]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[11]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[12]  O. Schnell,et al.  Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[13]  D N Mendelson,et al.  Health care expenditures for people with diabetes mellitus, 1992. , 1994, The Journal of clinical endocrinology and metabolism.

[14]  A. Marette,et al.  Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  M. Harris,et al.  Diabetes and decline in heart disease mortality in US adults. , 1999, JAMA.

[16]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[17]  J. Gore,et al.  Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. , 2004, Archives of internal medicine.

[18]  Zygimantas Cepaitis,et al.  Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. , 2005, Diabetes.

[19]  M. Bartnik Glucose regulation and coronary artery disease : Studies on prevalence, recognition and prognostic implications , 2005 .

[20]  D. Barbier [Depression in the elderly. Clinical aspects]. , 2001, Presse medicale.

[21]  M. Chaney,et al.  Attempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycemia. , 1999, Anesthesia and analgesia.

[22]  E. Ford The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. , 2004, Atherosclerosis.

[23]  W. C. Sheldon,et al.  Reconstructive Coronary Artery Surgery: Postoperative Assessment , 1969, Circulation.

[24]  R. Detrano,et al.  Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. , 2004, JAMA.

[25]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[26]  M. Apkon,et al.  Persistent hyperglycemia in critically ill children. , 2005, The Journal of pediatrics.

[27]  J. Shaw,et al.  Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality , 1999, Diabetologia.

[28]  F. Tediosi,et al.  Costs of diabetes. A methodological analysis of the literature. , 1999, PharmacoEconomics.

[29]  P. Bennett,et al.  Follow-up of the WHO multinational study of vascular disease in diabetes: general description and morbidity , 2001, Diabetologia.

[30]  B. Mitchell,et al.  Screening for silent coronary heart disease in type 2 diabetes: clinical application of American Diabetes Association guidelines. , 2006, Diabetes care.

[31]  James W. Anderson,et al.  Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[32]  L. Bouter,et al.  Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. , 2005, Diabetes care.

[33]  T. Valle,et al.  Occupational, commuting, and leisure-time physical activity in relation to risk for Type 2 diabetes in middle-aged Finnish men and women , 2003, Diabetologia.

[34]  R. Califf,et al.  Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). , 1999, Circulation.

[35]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[36]  Arno W. Hoes,et al.  Peripheral arterial disease in the elderly: The Rotterdam Study. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[37]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[38]  R. Wolfe,et al.  TNF directly stimulates glucose uptake and leucine oxidation and inhibits FFA flux in conscious dogs. , 1996, The American journal of physiology.

[39]  Jagmeet P. Singh,et al.  Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). , 2000, The American journal of cardiology.

[40]  A Hofman,et al.  Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. , 1999, European heart journal.

[41]  J. P. O’Hare,et al.  The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. , 1986, The Quarterly journal of medicine.

[42]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[43]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.

[44]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[45]  A. Hamsten,et al.  Insulin, intact and split proinsulin, and coronary artery disease in young men. , 1995, Circulation.

[46]  G. L’italien,et al.  Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. , 2003, The American journal of cardiology.

[47]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[48]  E. Vittinghoff,et al.  Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial , 2003, Annals of Internal Medicine.

[49]  B. Rutherford,et al.  Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. , 2003, American heart journal.

[50]  Miet Schetz,et al.  Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. , 2006, European heart journal.

[51]  P. Serruys,et al.  Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). , 2005, American Journal of Cardiology.

[52]  C. Lan,et al.  Prevalence of stroke in Taiwan. , 1989, Stroke.

[53]  A. Maggioni,et al.  Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. , 1997, Circulation.

[54]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[55]  Diederick Grobbee,et al.  Randomized Comparison Between Stenting and Off-Pump Bypass Surgery in Patients Referred for Angioplasty , 2003, Circulation.

[56]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[57]  J. Hsia,et al.  Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes , 2006, Diabetes Care.

[58]  N. Waugh,et al.  Mortality From Cerebrovascular Disease in a Cohort of 23 000 Patients With Insulin-Treated Diabetes , 2003, Stroke.

[59]  H. Gerstein,et al.  Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview , 2000, The Lancet.

[60]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[61]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[62]  Beverley Balkau,et al.  Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. , 2003, Diabetes care.

[63]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[64]  M. Simoons,et al.  Unstable angina: good long-term outcome after a complicated early course. , 1998, Journal of the American College of Cardiology.

[65]  Neil J Grey,et al.  Reduction of nosocomial infections in the surgical intensive-care unit by strict glycemic control. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[66]  C. Snehalatha,et al.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.

[67]  V. Katch,et al.  The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. , 1989, The New England journal of medicine.

[68]  L. Rydén,et al.  Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus , 2005, Diabetes & vascular disease research.

[69]  Georgeanne Botek,et al.  Treatment for diabetic foot ulcers , 2005, The Lancet.

[70]  C. Imray,et al.  Are some strokes preventable? The potential role of transcranial doppler in transient ischaemic attacks of carotid origin , 2005, The Lancet Neurology.

[71]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[72]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[73]  B. Howard,et al.  Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes , 1998, Diabetologia.

[74]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[75]  S. Solomon,et al.  Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial , 2004, Circulation.

[76]  J. Huttunen,et al.  Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study , 1992, Diabetes Care.

[77]  M. Omata,et al.  Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. , 1997, Journal of the American College of Cardiology.

[78]  Farris K. Timimi,et al.  Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. , 1996, The Journal of clinical investigation.

[79]  E. Standl,et al.  The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus , 2003, Diabetologia.

[80]  G. Tinkoff,et al.  Admission hyperglycemia as a prognostic indicator in trauma. , 2003, The Journal of trauma.

[81]  J. Sturis,et al.  Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. , 1996, The New England journal of medicine.

[82]  K. Malmberg,et al.  Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.

[83]  A Hofman,et al.  The prognosis of heart failure in the general population: The Rotterdam Study. , 2001, European heart journal.

[84]  I. Palacios,et al.  Drug-eluting stents for diabetes mellitus: a rush to judgment? , 2005, Journal of the American College of Cardiology.

[85]  T. Marwick,et al.  Effects of glucose–insulin–potassium infusion on chronic ischaemic left ventricular dysfunction , 2003, Heart.

[86]  G. Radda,et al.  Uncoupling proteins in human heart , 2004, The Lancet.

[87]  D. Porte,et al.  Glycosylated Hemoglobin and Fasting Plasma Glucose in the Assessment of Outpatient Glycemic Control in NIDDM , 1982, Diabetes Care.

[88]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.

[89]  W. Koenig,et al.  The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. , 2000, Diabetologia.

[90]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[91]  S. Pocock,et al.  Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting , 1998, The Lancet.

[92]  P. Stacpoole,et al.  Effects of dichloroacetate in patients with congestive heart failure , 1998, Clinical cardiology.

[93]  D. Betteridge,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial☆ , 2004 .

[94]  Tom Fahey,et al.  Predictive accuracy of the Framingham coronary risk score in British men:prospective cohort study , 2003, BMJ : British Medical Journal.

[95]  P. Dyck,et al.  Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[96]  R. Loewenson,et al.  Influence of Pancreas Transplantation on Cardiorespiratory Reflexes, Nerve Conduction, and Mortality in Diabetes Mellitus , 1990, Diabetes.

[97]  J. Killian,et al.  Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. , 2002, Journal of the American College of Cardiology.

[98]  F. Lobo,et al.  Direct health care costs of diabetic patients in Spain. , 2004, Diabetes care.

[99]  M L Simoons,et al.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.

[100]  R. D'Agostino,et al.  Risk of Hospitalized Stroke in Men Enrolled in the Honolulu Heart Program and the Framingham Study: A Comparison of Incidence and Risk Factor Effects , 2002, Stroke.

[101]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[102]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[103]  A. Hamsten,et al.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.

[104]  Darren K Mcguire,et al.  Influence of diabetes on long‐term outcome among unselected patients with acute coronary events , 2004, Scandinavian cardiovascular journal : SCJ.

[105]  R. Campbell,et al.  Management Strategies for a Better Outcome in Unstable Coronary Artery Disease , 1998, Clinical cardiology.

[106]  W. Weintraub,et al.  Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. , 1995, Circulation.

[107]  M. Mclean,et al.  The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. , 2006, Diabetes care.

[108]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[109]  B. Jönsson Diabetes--the cost of illness and the cost of control. An estimate for Sweden 1978. , 1983, Acta medica Scandinavica. Supplementum.

[110]  A. Hofman,et al.  Prevalence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study , 2002, Stroke.

[111]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[112]  N. Christensen,et al.  Hemodynamics in diabetic orthostatic hypotension. , 1981, The Journal of clinical investigation.

[113]  M. Fowler Clinical Practice Recommendations , 2009, Clinical Diabetes.

[114]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[115]  D. Kereiakes,et al.  Metabolic syndrome epidemic. , 2003, Circulation.

[116]  Catherine Kim,et al.  Gestational diabetes and the incidence of type 2 diabetes: a systematic review. , 2002, Diabetes care.

[117]  J. W. Box,et al.  Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study , 2000 .

[118]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[119]  V. Gudnason,et al.  Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study , 2005, European Journal of Cardiovascular Prevention & Rehabilitation.

[120]  M. Rewers,et al.  Global Estimates for Prevalence of Diabetes Mellitus and Impaired Glucose Tolerance in Adults , 1993, Diabetes Care.

[121]  A. K. Jonassen,et al.  Glucose-Insulin-Potassium Reduces Infarct Size When Administered During Reperfusion , 2000, Cardiovascular Drugs and Therapy.

[122]  M. Laakso,et al.  Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women , 2005, Diabetologia.

[123]  J. Stamler,et al.  Asymptomatic hyperglycemia and coronary heart disease. A series of papers by the International Collaborative Group, based on studies in fifteen populations. Introduction. , 1979, Journal of chronic diseases.

[124]  G. Fonarow,et al.  Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. , 2005, American heart journal.

[125]  N. Ray,et al.  Economic Consequences of Diabetes Mellitus in the U.S. in 1997 , 1998, Diabetes Care.

[126]  B. Howard,et al.  Diabetes and cardiovascular disease , 2000, Annual review of medicine.

[127]  J. Hokanson,et al.  Dyslipidemia of central obesity and insulin resistance. , 1999, Diabetes Care.

[128]  S. Grundy Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. , 1999, The American journal of cardiology.

[129]  B. Lüderitz,et al.  Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism , 2003, Heart.

[130]  M. Pirisi,et al.  Hyperglycemia-Induced Thrombin Formation in Diabetes: The Possible Role of Oxidative Stress , 1995, Diabetes.

[131]  Bendix Carstensen,et al.  A Danish diabetes risk score for targeted screening: the Inter99 study. , 2004, Diabetes care.

[132]  P. Serruys,et al.  Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients: Insights From the Arterial Revascularization Therapy Study (ARTS) Trial , 2001, Circulation.

[133]  Carmen Castaneda-Sceppa,et al.  Physical activity/exercise and type 2 diabetes. , 2004, Diabetes care.

[134]  G. Stone,et al.  Short- and long-term results after multivessel stenting in diabetic patients. , 2004, Journal of the American College of Cardiology.

[135]  P. Whelton,et al.  Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2005 .

[136]  P. Whelton,et al.  Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. , 2001, Archives of internal medicine.

[137]  M. Hanefeld,et al.  Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. , 2000, Diabetes care.

[138]  E. Falk,et al.  Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 2003, European heart journal.

[139]  J. Hopper,et al.  Stroke topography and outcome in relation to hyperglycaemia and diabetes. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[140]  D. Moliterno,et al.  Diabetes and percutaneous coronary intervention: the sweet smell of success? , 2003, American heart journal.

[141]  S. Shinnar,et al.  The trials and tribulations of pediatric drug trials , 2005, Neurology.

[142]  M. Borger,et al.  Prevention and management of deep sternal wound infection. , 2004, Seminars in thoracic and cardiovascular surgery.

[143]  Mckendry Jb Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. , 1989 .

[144]  S. Neugebauer,et al.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention. , 1997, Drugs.

[145]  B. Jönsson,et al.  The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial , 1999, Diabetologia.

[146]  S. Yusuf,et al.  Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.

[147]  Daniel L. McGee,et al.  Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.

[148]  M. Muggeo,et al.  Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. , 1996, Diabetes care.

[149]  Greet Van den Berghe,et al.  How does blood glucose control with insulin save lives in intensive care , 2004 .

[150]  W. Rathmann,et al.  Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. , 1993, Diabete & metabolisme.

[151]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[152]  J. Pomposelli,et al.  Effect of interleukin-1 and tumor necrosis factor/cachectin on glucose turnover in the rat. , 1990, Metabolism: clinical and experimental.

[153]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[154]  A. Malhotra,et al.  Stress-induced hyperglycemia. , 2001, Critical care clinics.

[155]  T. Nhlapo Women and the constitution: what to do when culture strikes back. , 1992, Southern Africa political & economic monthly.

[156]  SamuelLévy,et al.  Characterization of Different Subsets of Atrial Fibrillation in General Practice in France , 1999 .

[157]  CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[158]  E. Bonora,et al.  The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[159]  T. Münzel,et al.  Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus , 2001, Circulation research.

[160]  Kathryn Tan,et al.  Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004)* , 2005, Current medical research and opinion.

[161]  K. Borch-Johnsen,et al.  Hypertension in people with Type 2 diabetes: knowledge‐based diabetes‐specific guidelines , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[162]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[163]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[164]  G. Keresztury,et al.  Atherosclerosis in amputated legs of patients with and without diabetes mellitus. , 1998, International angiology : a journal of the International Union of Angiology.

[165]  S. Yusuf,et al.  Effect of ramipril on the incidence of diabetes. , 2006, The New England journal of medicine.

[166]  O'Neill Ww Multivessel balloon angioplasty should be abandoned in diabetic patients , 1998 .

[167]  T. Lüscher,et al.  Atherosclerosis and the two faces of endothelial nitric oxide synthase. , 1998, Circulation.

[168]  G. Shulman,et al.  Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction , 2002, European journal of clinical investigation.

[169]  S. Marso Optimizing the diabetic formulary: beyond aspirin and insulin. , 2002, Journal of the American College of Cardiology.

[170]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[171]  D. Giugliano,et al.  Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans , 1990, Diabetologia.

[172]  A. Kriska,et al.  Handbook of Exercise in Diabetes , 2004 .

[173]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[174]  A. Dyer,et al.  Diabetes, Asymptomatic Hyperglycemia, and 22-Year Mortality in Black and White Men: The Chicago Heart Association Detection Project in Industry Study , 1997, Diabetes Care.

[175]  R F Anda,et al.  Impact of multiple risk factor profiles on determining cardiovascular disease risk. , 1998, Preventive medicine.

[176]  E. Barrett-Connor,et al.  Diabetes mellitus: an independent risk factor for stroke? , 1988, American journal of epidemiology.

[177]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[178]  G. Rozanski,et al.  A Metabolic Mechanism For Cardiac K+ Channel Remodelling , 2002, Clinical and experimental pharmacology & physiology.

[179]  K. Narayan,et al.  Preventing Non-Insulin-Dependent Diabetes , 1995, Diabetes.

[180]  E Geraci,et al.  Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. , 2001, European heart journal.

[181]  J. Simoneau,et al.  Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. , 1994, The Journal of clinical investigation.

[182]  Walter C Willett,et al.  Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. , 2002, Diabetes care.

[183]  J. Tuomilehto,et al.  Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. , 2003, Diabetes care.

[184]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[185]  R. Holle,et al.  Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project , 1996, Diabetologia.

[186]  C. Bauters,et al.  Patency of Percutaneous Transluminal Coronary Angioplasty Sites at 6-Month Angiographic Follow-Up: A Key Determinant of Survival in Diabetics After Coronary Balloon Angioplasty , 2001, Circulation.

[187]  R. Holman,et al.  Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) , 2005, Diabetologia.

[188]  A. Vinik Diagnosis and management of diabetic neuropathy. , 1999, Clinics in geriatric medicine.

[189]  U Ravens,et al.  Task Force on Sudden Cardiac Death of the European Society of Cardiology. , 2001, European heart journal.

[190]  B. Gersh,et al.  Methods of coronary revascularization--things may not be as they seem. , 2005, The New England journal of medicine.

[191]  C. Cogbill,et al.  Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? , 2003, Journal of the American College of Cardiology.

[192]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[193]  L. Sjöström,et al.  Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. , 1983, The Journal of clinical investigation.

[194]  A. Jacobs,et al.  Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). , 2002, The American journal of cardiology.

[195]  T. Kuzuya,et al.  Classification of Diabetes on the Basis of Etiologies Versus Degree of Insulin Deficiency , 1997, Diabetes Care.

[196]  D. Mikhailidis,et al.  Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus , 2003, Angiology.

[197]  Z. Bloomgarden American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. , 2003, Diabetes care.

[198]  A. Kissebah,et al.  Relation of Body Fat Distribution to Metabolic Complications of Obesity , 1982 .

[199]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[200]  B. Horne,et al.  Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. , 2003, American heart journal.

[201]  G. Deichsel,et al.  DRUG-INDUCED INHIBITION OF PLATELET FUNCTION DELAYS PROGRESSION OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE A Prospective Double-Blind Arteriographically Controlled Trial , 1985, The Lancet.

[202]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[203]  G. Leese,et al.  The Management of Hypertension in Diabetes: with Special Reference to Diabetic Kidney Disease , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[204]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[205]  R. Herings,et al.  Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme , 1995, The Lancet.

[206]  Matthijs Oudkerk,et al.  Incidence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study , 2003, Stroke.

[207]  Chalmers Tc,et al.  A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. , 1994, International angiology : a journal of the International Union of Angiology.

[208]  S. Anker,et al.  Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. , 1997, Journal of the American College of Cardiology.

[209]  James Stephen Krinsley,et al.  Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. , 2004, Mayo Clinic proceedings.

[210]  C. Bauters,et al.  Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. , 1999, Journal of the American College of Cardiology.

[211]  L. Landsberg Insulin resistance and the metabolic syndrome , 2005, Diabetologia.

[212]  J Wayne Meredith,et al.  Relationship of early hyperglycemia to mortality in trauma patients. , 2004, The Journal of trauma.

[213]  C. Furberg,et al.  Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. , 1989, BMJ.

[214]  L. Elveback,et al.  Transient ischemic attack and stroke in a community-based diabetic cohort. , 1983, Mayo Clinic proceedings.

[215]  C H Lang,et al.  Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. , 1992, Endocrinology.

[216]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[217]  C. Gullion,et al.  The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.

[218]  L. Rydén,et al.  Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study , 2005, Diabetologia.

[219]  T. Songer The economic costs of NIDDM. , 1992, Diabetes/metabolism reviews.

[220]  B. Zinman,et al.  Physical activity/exercise and diabetes mellitus. , 2003, Diabetes care.

[221]  C. Palmer,et al.  Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) , 2003, Hypertension.

[222]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[223]  U. Goldbourt,et al.  Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. , 1996, The American journal of cardiology.

[224]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[225]  J. Ottervanger,et al.  Treatment decisions in stable coronary artery disease: insights from the Euro Heart Survey on Coronary Revascularization. , 2006, The Journal of thoracic and cardiovascular surgery.

[226]  G. Albers,et al.  Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[227]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[228]  W. C. Sheldon,et al.  Reconstructive coronary artery surgery. Venous autograft technique. , 1970, JAMA.

[229]  A. Hedley,et al.  A prospective population based study of gender differential in mortality from cardiovascular disease and "all causes" in asymptomatic hyperglycaemics. , 1994, Journal of clinical epidemiology.

[230]  Philip P Goodney,et al.  Current status of carotid artery stenting. , 2006, Journal of vascular surgery.

[231]  P. Wolf,et al.  Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.

[232]  Helmut Schulte,et al.  Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. , 2003, European heart journal.

[233]  J. Tuomilehto,et al.  Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. , 2000, Diabetes care.

[234]  M. Blombäck,et al.  Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. , 2003, Diabetes care.

[235]  James T. Willerson,et al.  Appointment of New Associate Editor for Circulation , 1996 .

[236]  D. Dhanwal,et al.  Silent myocardial ischaemia in patients with type II diabetes mellitus and its relation with autonomic dysfunction. , 2000, Indian heart journal.

[237]  M. Mack,et al.  Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass. , 2001, The Annals of thoracic surgery.

[238]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[239]  P. Poole‐Wilson,et al.  Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. , 2000, European heart journal.

[240]  L. Wilhelmsen,et al.  Heart failure in the general population of men--morbidity, risk factors and prognosis. , 2001, Journal of internal medicine.

[241]  S. Saydah,et al.  Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. , 2001, Diabetes care.

[242]  J. Muller,et al.  Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. , 2001, Diabetes care.

[243]  K. Eriksson,et al.  Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise The 6-year Malmö feasibility study , 1991, Diabetologia.

[244]  Patrick W Serruys,et al.  The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. , 2006, American heart journal.

[245]  P. Herrero,et al.  Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[246]  M. Laakso,et al.  European Stroke Prevention Study: Effectiveness of Antiplatelet Therapy in Diabetic Patients in Secondary Prevention of Stroke , 1992, Stroke.

[247]  D. Lawlor,et al.  Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women’s Heart and Health Study , 2005, Diabetologia.

[248]  T. Jørgensen,et al.  A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. , 2002, International journal of epidemiology.

[249]  S. Haffner,et al.  Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome , 1991, Diabetologia.

[250]  JoAnn E. Manson,et al.  Prospective Study of Sudden Cardiac Death Among Women in the United States , 2003, Circulation.

[251]  T. Lüscher,et al.  High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells: Role of Protein Kinase C and Reactive Oxygen Species , 2003, Circulation.

[252]  M. Cybulsky,et al.  Advanced Glycation Endproducts Promote Adhesion Molecule (VCAM-1, ICAM-1) Expression and Atheroma Formation in Normal Rabbits , 1995, Molecular medicine.

[253]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomized controlled trial☆ , 2003 .

[254]  G. Sundkvist,et al.  A 14‐year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[255]  W. Tamborlane,et al.  The normal glucose tolerance continuum in obese youth: evidence for impairment in beta-cell function independent of insulin resistance. , 2005, The Journal of clinical endocrinology and metabolism.

[256]  A. Pfeiffer,et al.  Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro , 2001, Diabetologia.

[257]  M. Laakso,et al.  Age of Onset and Type of Diabetes , 1985, Diabetes Care.

[258]  A. Shehadeh,et al.  Cardiac consequences of diabetes mellitus , 1995, Clinical cardiology.

[259]  E. Barrett-Connor,et al.  Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. , 1991, American journal of epidemiology.

[260]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[261]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[262]  L. Rydén,et al.  Abnormal glucose tolerance – a common risk factor in patients with acute myocardial infarction in comparison with population‐based controls , 2004, Journal of internal medicine.

[263]  E. Gale The myth of the metabolic syndrome , 2005, Diabetologia.

[264]  S. Yusuf,et al.  Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. , 2005, Canadian journal of physiology and pharmacology.

[265]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity after acute myocardial infarction: The OPTIMAAL randomized trial. , 2002 .

[266]  K. Yano,et al.  Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. , 1995, Circulation.

[267]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[268]  M. Wallander,et al.  Incidence of newly diagnosed heart failure in UK general practice , 2001, European journal of heart failure.

[269]  C. Östenson,et al.  Direct medical costs for patients with type 2 diabetes in Sweden , 2000, Journal of internal medicine.

[270]  L. Monti,et al.  Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. , 2003, American heart journal.

[271]  E. Standl,et al.  Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[272]  Steven Blair,et al.  Low Cardiorespiratory Fitness and Physical Inactivity as Predictors of Mortality in Men with Type 2 Diabetes , 2000, Annals of Internal Medicine.

[273]  Miet Schetz,et al.  Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control* , 2003, Critical care medicine.

[274]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[275]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[276]  H. Lithell,et al.  Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data , 1998 .

[277]  E. Barrett-Connor,et al.  Isolated Postchallenge Hyperglycemia and the Risk of Fatal Cardiovascular Disease in Older Women and Men: The Rancho Bernardo Study , 1998, Diabetes Care.

[278]  A. Cowley,et al.  Beneficial haemodynamic effects of insulin in chronic heart failure , 2001, Heart.

[279]  M. Laakso,et al.  Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. , 1996, Stroke.

[280]  I. U. Haq,et al.  Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men , 1999, Heart.

[281]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[282]  T. Lüscher,et al.  Enhanced Peroxynitrite Formation Is Associated with Vascular Aging , 2000, The Journal of experimental medicine.

[283]  N. Kouchoukos,et al.  Risks of bilateral internal mammary artery bypass grafting. , 1990, The Annals of thoracic surgery.

[284]  R. Califf,et al.  Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). , 1999, Circulation.

[285]  Jun Zhu,et al.  Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. , 2005, JAMA.

[286]  Z. Naito,et al.  Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. , 1998, Journal of atherosclerosis and thrombosis.

[287]  L. Chambless,et al.  Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. , 2005, Diabetes care.

[288]  R. Holman,et al.  Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. , 1999, Archives of internal medicine.

[289]  G. Van den Berghe,et al.  Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. , 2003, The Journal of clinical endocrinology and metabolism.

[290]  E. Jones,et al.  Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. , 1999, The Annals of thoracic surgery.

[291]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[292]  D. Yellon,et al.  Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival Signaling , 2001, Circulation research.

[293]  H. Ginsberg,et al.  The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis , 2000, Journal of cardiovascular risk.

[294]  L. Landsberg Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why) , 2001, Journal of hypertension.

[295]  K. Forrest,et al.  Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. , 2003, Diabetes care.

[296]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[297]  E. Kraegen,et al.  Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes , 1988, Diabetes.

[298]  Å. Lernmark,et al.  β-Cell Function in Relation to Islet Cell Antibodies During the First 3 Yr After Clinical Diagnosis of Diabetes in Type II Diabetic Patients , 1993, Diabetes Care.

[299]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[300]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[301]  K. Beatt,et al.  Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. , 1997, Circulation.

[302]  G. Dailey,et al.  Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. , 1995, JAMA.

[303]  Seppo Lehto,et al.  Gender difference in the impact of type 2 diabetes on coronary heart disease risk. , 2004, Diabetes care.

[304]  Gianni Tognoni,et al.  Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. , 2005, Diabetes care.

[305]  M. Kaste,et al.  Recommendations for the Management of Intracranial Haemorrhage – Part I: Spontaneous Intracerebral Haemorrhage , 2006, Cerebrovascular Diseases.

[306]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[307]  H. Adachi,et al.  Is insulin resistance or diabetes mellitus associated with stroke? An 18-year follow-up study. , 2001, Diabetes research and clinical practice.

[308]  Tomás Pantoja,et al.  Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22. , 2003 .

[309]  F Bruyninckx,et al.  Insulin therapy protects the central and peripheral nervous system of intensive care patients , 2005, Neurology.

[310]  T. Orchard The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Annals of medicine.

[311]  C. Bogardus,et al.  Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. , 2001, Diabetes care.

[312]  E. Hannan,et al.  Outcomes of planned home births with certified professional midwives: large prospective study in North America , 2005, BMJ : British Medical Journal.

[313]  E. Mannarino,et al.  Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. , 2004, Atherosclerosis.

[314]  R. Califf,et al.  Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. , 1997, American heart journal.

[315]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[316]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[317]  L H Kuller,et al.  Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.

[318]  M. Creager,et al.  -.____----.---_-Impaired Nitric Oxide-Mediated Vasodilation in Patients With Non-Insulin-Dependent Diabetes Mellitw , 2016 .

[319]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[320]  K. Malmberg Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[321]  H. Diener,et al.  European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.

[322]  G. Gallus,et al.  Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. , 2003, Diabetes care.

[323]  D. C. Warner,et al.  Costs of diabetes in Texas, 1992 , 1996, Diabetes Care.

[324]  N. Doll,et al.  Impact of Diabetes Mellitus on Cardiac Surgery Outcome , 2003, The Thoracic and cardiovascular surgeon.

[325]  B. Gage,et al.  Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.

[326]  L. Rydén,et al.  Effects of Trimetazidine on Left Ventricular Function in Patients with Type 2 Diabetes and Heart Failure , 2004, Journal of cardiovascular pharmacology.

[327]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[328]  E. Vartiainen,et al.  The North Karelia project : 20 year results and experiences , 1995 .

[329]  Jaakko Tuomilehto,et al.  Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. , 2006, Diabetes care.

[330]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[331]  R. de Caterina,et al.  Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. , 2004, European heart journal.

[332]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[333]  R. Schiele,et al.  Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study , 2003, Acta Diabetologica.

[334]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[335]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[336]  Kurt J Greenlund,et al.  Sex Differences in US Mortality Rates for Stroke and Stroke Subtypes by Race/Ethnicity and Age, 1995–1998 , 2002, Stroke.

[337]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[338]  F. Cambien,et al.  Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes , 1989, Diabetologia.

[339]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[340]  G. Sundkvist,et al.  Capillary Blood on Filter Paper for Determination of HbA1c by Ion Exchange Chromatography , 1996, Diabetes Care.

[341]  Ralph B D'Agostino,et al.  Trends in cardiovascular complications of diabetes. , 2004, JAMA.

[342]  R. Jones,et al.  Mediastinitis After Coronary Artery Bypass Graft Surgery: Risk Factors and Long‐Term Survival , 1995, Circulation.

[343]  D. Wennberg,et al.  Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. , 2001, Journal of the American College of Cardiology.

[344]  G Hu,et al.  Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study , 2004, Diabetologia.

[345]  C. Edwards International Textbook of Diabetes Mellitus , 2004 .

[346]  J. Wilberger,et al.  The impact of hyperglycemia on patients with severe brain injury. , 2005, The Journal of trauma.

[347]  Gerardo Heiss,et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.

[348]  J. Tuomilehto,et al.  Occupational, Commuting, and Leisure-Time Physical Activity in Relation to Total and Cardiovascular Mortality Among Finnish Subjects With Type 2 Diabetes , 2004, Circulation.

[349]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[350]  J. Tuomilehto,et al.  The major diabetes prevention trials , 2003, Current diabetes reports.

[351]  P. Iozzo,et al.  Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. , 2002, Diabetes.

[352]  Oliver Schnell,et al.  Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction: the Munich registry. , 2004, Diabetes care.

[353]  L. Piegas,et al.  Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial , 1998 .

[354]  W. Hiatt,et al.  Medical treatment of peripheral arterial disease and claudication. , 2001, The New England journal of medicine.

[355]  M. Sclavo [Physical activity and risk for cardiovascular events in diabetic women]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[356]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[357]  E. Mayer-Davis,et al.  Nutrition and prevention of type 2 diabetes. , 2003, Annual review of nutrition.

[358]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[359]  V. Salomaa,et al.  Glucose tolerance and blood pressure: long term follow up in middle aged men. , 1991, BMJ.

[360]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[361]  康生 大久保,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study , 1995 .

[362]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[363]  W. Koenig,et al.  The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? , 2000, Diabetologia.

[364]  Andrew Briggs,et al.  Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals , 2005, The Lancet.

[365]  M. Engelgau,et al.  Screening for type 2 diabetes. , 2000, Diabetes care.

[366]  R. Narayan,et al.  The influence of diabetes mellitus on outcome from subarachnoid hemorrhage. , 1991, Diabetes research.

[367]  M. Laakso,et al.  Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes , 2000, Diabetologia.

[368]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[369]  M. Hanefeld,et al.  Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. , 2004, The Journal of clinical endocrinology and metabolism.

[370]  R B D'Agostino,et al.  Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.

[371]  Po Box,et al.  Excess risk of fatal coronary heart disease associated with diabetes in men and women:meta-analysis of 37 prospective cohort studies , 2006 .

[372]  G. Habib,et al.  Silent myocardial ischemia in patients with diabetes: who to screen. , 1999, Diabetes care.

[373]  W. Kannel,et al.  Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.

[374]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[375]  H Wedel,et al.  Infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Glycometabolic State at Admission : Important Risk Marker of Mortality in , 1999 .

[376]  K. Malmberg,et al.  Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. , 2003, European heart journal.

[377]  I. Palacios,et al.  Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. , 2001, Journal of the American College of Cardiology.

[378]  M. Muggeo,et al.  Cardiovascular Disease and Its Risk Factors in IDDM in Europe , 1996, Diabetes Care.

[379]  U. Das Is insulin an endogenous cardioprotector? , 2002, Critical care.

[380]  E. Topol,et al.  Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. , 2004, European heart journal.

[381]  G. Davey Smith,et al.  Physical activity and cause‐specific mortality in men with Type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[382]  M. Turina,et al.  [Percutaneous transluminal dilatation of chronic coronary stenoses. First experiences]. , 1978, Swiss medical weekly.

[383]  N. Vaughan Report of the 8th EASD-DOIT Study Group Workshop "Decision Support in Diabetes Care" Stirling Royal Infirmary, Stirling, UK, 7-8 September 2001. , 2002, Diabetologia.

[384]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[385]  M. Hanefeld,et al.  A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[386]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[387]  Bari Investigators Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. , 2000, Journal of the American College of Cardiology.

[388]  I. S. Klemasev Myocardial infarction in patients with diabetes mellitus. , 1967 .

[389]  F. Murad,et al.  Protein Nitration in Cardiovascular Diseases , 2002, Pharmacological Reviews.

[390]  J. Ottervanger,et al.  Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. , 2005, The American journal of cardiology.

[391]  Deepak L. Bhatt,et al.  Abciximab reduces mortality in diabetics following percutaneous coronary intervention. , 2000, Journal of the American College of Cardiology.

[392]  A. Sniderman,et al.  Low Density Lipoprotein: A METABOLIC PATHWAY FOR RETURN OF CHOLESTEROL TO THE SPLANCHNIC BED , 1978 .

[393]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation. , 2001, Chest.

[394]  M. Laakso,et al.  Structure and Costs of Health Care of Diabetic Patients in Finland , 1996, Diabetes Care.

[395]  D. Ziegler,et al.  Stroke in patients with diabetes mellitus , 2004, Diabetes/metabolism research and reviews.

[396]  M. Laakso,et al.  Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.

[397]  G. Reaven Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[398]  B. Danielsson,et al.  Dicyclomine hydrochloride in infantile colic. , 1985, British medical journal.

[399]  J. Tuomilehto,et al.  Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction , 2005, Diabetologia.

[400]  J Herlitz,et al.  Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. , 2005, European heart journal.

[401]  B. Jönsson,et al.  Revealing the cost of Type II diabetes in Europe , 2002, Diabetologia.

[402]  D. Ewing,et al.  The natural history of diabetic autonomic neuropathy. , 1980, The Quarterly journal of medicine.

[403]  M. Pfeffer,et al.  Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.

[404]  F. Cappuccio,et al.  Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study , 2002, BMJ : British Medical Journal.

[405]  M. Apkon,et al.  Hyperglycemia in Critically Ill Children: 21 , 2005 .

[406]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[407]  KazuomiKario,et al.  Activation of Tissue Factor–Induced Coagulation and Endothelial Cell Dysfunction in Non–Insulin-Dependent Diabetic Patients With Microalbuminuria , 1995 .

[408]  G. Nijpels,et al.  The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups: data from the 1999 health survey for England. , 2004, Diabetes care.

[409]  T. Bowker,et al.  Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. , 2001, The American journal of cardiology.

[410]  I. Hirsch,et al.  Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM , 1994, Diabetes.

[411]  Tseng Chin-Hsiao The Costs of Diabetes , 2000 .

[412]  G. Hu,et al.  Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes , 2003, Diabetologia.

[413]  S. Lillioja,et al.  Relationship between degree of obesity and in vivo insulin action in man. , 1985, The American journal of physiology.

[414]  A. Sniderman,et al.  Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[415]  J. Meigs,et al.  Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. , 2000, American journal of epidemiology.

[416]  T. B. Investigators,et al.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.

[417]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[418]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[419]  N. Maurits,et al.  Admitting Acute Ischemic Stroke Patients to a Stroke Care Monitoring Unit Versus a Conventional Stroke Unit: A Randomized Pilot Study , 2003, Stroke.

[420]  Daniel Levy,et al.  Arrhythmias: abstractA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study☆ , 2003 .

[421]  J. Tu,et al.  Risk Factors for Death or Stroke After Carotid Endarterectomy: Observations From the Ontario Carotid Endarterectomy Registry , 2003, Stroke.

[422]  D. Faxon,et al.  Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.

[423]  J. Remes,et al.  Incidence of heart failure in eastern Finland: a population-based surveillance study. , 1992, European heart journal.

[424]  V. Fuster,et al.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.

[425]  H. Gerstein,et al.  The Economic Cost of Diabetes in Canada, 1998 , 2002 .

[426]  H. Taegtmeyer Cardiac metabolism as a target for the treatment of heart failure. , 2004, Circulation.

[427]  Ilse Vanhorebeek,et al.  Intensive insulin therapy protects the endothelium of critically ill patients. , 2005, The Journal of clinical investigation.

[428]  P. Deedwania,et al.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. , 2005, American heart journal.

[429]  E. Guallar,et al.  Meta-Analysis of Randomized Educational and Behavioral Interventions in Type 2 Diabetes , 2003, The Diabetes educator.

[430]  A. Bernstein,et al.  A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA , 2003, Neurology.

[431]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[432]  N. Gratsianskiĭ [Expert consensus document on the use of antiplatelet agents]. , 2004, Kardiologiia.

[433]  G. Paolisso,et al.  Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.

[434]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[435]  M. Hanefeld,et al.  Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.

[436]  D. Toni,et al.  Does hyperglycaemia play a role on the outcome of acute ischaemic stroke patients? , 1992, Journal of Neurology.

[437]  F. Fernández‐Avilés,et al.  Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.

[438]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[439]  P. Whelton,et al.  Risk of End-stage Renal Disease in Diabetes Mellitus: A Prospective Cohort Study of Men Screened for MRFIT , 1997 .

[440]  James Stephen Krinsley,et al.  Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. , 2003, Mayo Clinic proceedings.

[441]  L. Wallentin,et al.  Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study , 2002, The Lancet.

[442]  A. Manto,et al.  Blunted erythropoietin response to anemia in type 1 diabetic patients. , 1999, Diabetes care.

[443]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[444]  E. Antman Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. , 2003, American heart journal.

[445]  E. Frank Book Review Women's Mental Health: A Life-Cycle Approach Edited by Sarah E. Romans and Mary V. Seeman. 414 pp. Philadelphia, Lippincott Williams & Wilkins, 2005. $59.95. 0-7817-5129-2 , 2005 .

[446]  T. Deckert,et al.  Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. , 1978, Diabetologia.

[447]  Deepak L. Bhatt,et al.  Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. , 2004, Archives of internal medicine.

[448]  S. Milstien,et al.  Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. , 1999, Biochemical and biophysical research communications.

[449]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[450]  Pd redaction Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. , 2002, Diabetes care.

[451]  S. Haffner,et al.  Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? , 2004, Diabetes care.

[452]  T. Hedner,et al.  Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension–2 , 2000, Journal of hypertension.

[453]  M. Gheorghiade,et al.  &bgr;-Blockers in the Post-Myocardial Infarction Patient , 2002, Circulation.

[454]  Carl J Caspersen,et al.  Relationship of walking to mortality among US adults with diabetes. , 2003, Archives of internal medicine.

[455]  S. Fava,et al.  The Prognostic Value of Blood Glucose in Diabetic Patients with Acute Myocardial Infarction , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[456]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .

[457]  S. Haffner,et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.

[458]  H. Yki-Järvinen Comparison of insulin regimens for patients with type 2 diabetes , 2000 .

[459]  S. Fowler,et al.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. , 2005, Diabetes care.

[460]  T. Blanck,et al.  VOLATILE ANESTHETIC DEPRESSION OF CALCIUM CHANNELS IN BRAIN MEMBRANES , 1989 .

[461]  L. Opie,et al.  Propranolol and experimental myocardial infarction: substrate effects. , 1976, Postgraduate medical journal.

[462]  I. O'Brien,et al.  The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. , 1991, The Quarterly journal of medicine.

[463]  M. Marre,et al.  Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee. , 2000, Diabetes care.

[464]  R. Califf,et al.  Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction , 1997 .

[465]  D. Singer,et al.  The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it? , 1997, The Lancet.

[466]  W C Willett,et al.  The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. , 2001, Archives of internal medicine.

[467]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[468]  E. Barrett,et al.  Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. , 2004, Diabetes care.

[469]  P. Clemmensen,et al.  The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study. , 2004, European heart journal.

[470]  Mark Hargreaves,et al.  Adrenaline increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans , 2001, The Journal of physiology.

[471]  P. Bennett,et al.  Medial arterial calcification and its association with mortality and complications of diabetes , 1988, Diabetologia.

[472]  H. Barnhart,et al.  Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. , 1996, Circulation.

[473]  S. Priori,et al.  2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension , 2004, Heart Drug.

[474]  J. Leahy Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial , 2007 .

[475]  F. Cosentino,et al.  Diabetes and Inflammation , 2004, Herz.

[476]  T. Chalmers,et al.  A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. , 1994, International angiology : a journal of the International Union of Angiology.

[477]  R. Macko,et al.  Thrombomodulin deficiency in human diabetic nerve microvasculature. , 2002, Diabetes.

[478]  N. Tofil,et al.  Should you treat high glucose? A critical appraisal of "Persistent hyperglycemia in critically ill children" by Faustino and Apkon. (J Pediatr 2005; 146:30-34) , 2007 .

[479]  K. Lachapelle,et al.  Maintenance of Normoglycemia During Cardiac Surgery , 2004, Anesthesia and analgesia.

[480]  A. Chinaglia,et al.  QT interval, cardiovascular risk factors and risk of death in diabetes , 2004, Journal of endocrinological investigation.

[481]  S. Yusuf,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.

[482]  J. Evans,et al.  ACE Inhibitor Use Is Associated With Hospitalization for Severe Hypoglycemia in Patients With Diabetes , 1997, Diabetes Care.

[483]  G. Van den Berghe,et al.  Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. , 2003, Endocrinology.

[484]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[485]  Robert L. Frye,et al.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. , 1996, The New England journal of medicine.

[486]  R. Bucala,et al.  Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.

[487]  Dick M. Goedhart,et al.  Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. , 2005, American heart journal.

[488]  Eber,et al.  Effects of intensified lifestyle modification on the need for further revascularization after coronary angioplasty , 1999, European journal of clinical investigation.

[489]  R M Heethaar,et al.  Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. , 2001, Diabetes care.

[490]  L. Rydén,et al.  Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. , 1999, Diabetes care.

[491]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[492]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[493]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[494]  B. Howard,et al.  LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[495]  J. Tuomilehto,et al.  WHO MONICA Project: assessing CHD mortality and morbidity. , 1989, International journal of epidemiology.

[496]  W. Weaver,et al.  Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. , 2003, American heart journal.

[497]  S. Colagiuri The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. , 2004, European heart journal.

[498]  B. Howard,et al.  Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. , 2003, Diabetes care.

[499]  A. Barcelo,et al.  The cost of diabetes in Latin America and the Caribbean. , 2003, Bulletin of the World Health Organization.

[500]  Richard Hellman,et al.  American College of Endocrinology position statement on the insulin resistance syndrome. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[501]  J. Tayek,et al.  Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. , 2001, Clinical science.

[502]  F. Sones,et al.  Myocardial revascularization by internal mammary artery implant procedures. Clinical experience. , 1967, The Journal of thoracic and cardiovascular surgery.

[503]  B. Balkau,et al.  Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[504]  Y. Suematsu,et al.  Predictive risk factors for delayed extubation in patients undergoing coronary artery bypass grafting , 2000, Heart and Vessels.

[505]  B. Davis,et al.  Uniformity of captopril benefit in the SAVE study : subgroup analysis , 1994 .

[506]  M. Hanefeld,et al.  Das Metabolische Syndrom , 2006 .

[507]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[508]  S. Schmidt-Schweda,et al.  First clinical trial with etomoxir in patients with chronic congestive heart failure. , 2000, Clinical science.

[509]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[510]  W. Cherng,et al.  Modification of left ventricular isovolumic relaxation time during dobutamine echocardiography as a diagnostic method for ischemic heart disease. , 1997, Changgeng yi xue za zhi.

[511]  P. Wolf,et al.  Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. , 1990, JAMA.

[512]  R. Kahn,et al.  The metabolic syndrome: time for a critical appraisal , 2005, Diabetologia.

[513]  S. Punsar,et al.  Glucose tolerance and coronary heart disease: Helsinki policemen study. , 1979, Journal of chronic diseases.

[514]  R. Hamman,et al.  Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. , 1995, Circulation.

[515]  T. Valle,et al.  Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. , 2004, Archives of internal medicine.

[516]  L. Deckelbaum,et al.  Effect of plasma insulin level on myocardial blood flow and its mechanism of action. , 2000, The American journal of cardiology.

[517]  D. Clement A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[518]  N. Lamblin,et al.  Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.

[519]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[520]  A. Alavi,et al.  Relation of hyperglycemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome , 1990, Annals of neurology.

[521]  R. Cohen,et al.  Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. , 1991, The Journal of clinical investigation.

[522]  H. Diener,et al.  European Stroke Initiative Recommendations for Stroke Management – Update 2003 , 2003, Cerebrovascular Diseases.

[523]  P. Iozzo,et al.  Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes , 2002, Diabetologia.

[524]  E. Lengerich,et al.  The burden of diabetes in North Carolina. , 1995, North Carolina medical journal.

[525]  Ken Williams,et al.  National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study , 2004, Circulation.

[526]  Arshag D Mooradian,et al.  Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. , 2003, Diabetes care.

[527]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[528]  Jeffrey L Carson,et al.  Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. , 2002, Journal of the American College of Cardiology.

[529]  M. Olschewski,et al.  Glucose-insulin-potassium in cardiac surgery: a meta-analysis. , 2004, The Annals of thoracic surgery.

[530]  J. Salmerón,et al.  Diabetes in Mexico--a serious and growing problem. , 1992, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[531]  A. Vinik,et al.  Recognizing and treating diabetic autonomic neuropathy. , 2001, Cleveland Clinic journal of medicine.

[532]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[533]  M. Laakso,et al.  Dyslipidemia and Hyperglycemia Predict Coronary Heart Disease Events in Middle-Aged Patients With NIDDM , 1997, Diabetes.

[534]  J. Leahy The Metabolic Syndrome: Time for a Critical Appraisal: Joint Statement From the American Diabetes Association and the European Association for the Study of Diabetes , 2006 .

[535]  M. Dennis A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[536]  H. Löwel,et al.  High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000 , 2003, Diabetologia.

[537]  K. Yano,et al.  Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. , 1999, Diabetes care.

[538]  L. Rydén,et al.  Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. , 1989, European heart journal.

[539]  S. Arikian,et al.  THE COST‐EFFECTIVENESS OF DOXAZOSIN FOR THE TREATMENT OF HYPERTENSION IN TYPE II DIABETIC PATIENTS IN THE UK AND ITALY , 2001, International journal of clinical practice.

[540]  M. Laakso,et al.  Non‐Insulin‐Dependent Diabetes and Its Metabolic Control Are Important Predictors of Stroke in Elderly Subjects , 1994, Stroke.

[541]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[542]  J. Staessen,et al.  Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. , 2000, Archives of internal medicine.

[543]  Peter Jüni,et al.  Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. , 2006, American heart journal.

[544]  E. Rimm,et al.  Physical Activity in Relation to Cardiovascular Disease and Total Mortality Among Men With Type 2 Diabetes , 2003, Circulation.

[545]  David R. Wood,et al.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.

[546]  M. Engelgau,et al.  Prevention of type 2 diabetes: issues and strategies for identifying persons for interventions. , 2004, Diabetes technology & therapeutics.

[547]  K. Borch-Johnsen The new classification of diabetes mellitus and IGT: a critical approach. , 2001, Experimental and clinical endocrinology & diabetes.

[548]  D. Chinkes,et al.  Association of hyperglycemia with increased mortality after severe burn injury. , 2001, The Journal of trauma.

[549]  Maria Inês Schmidt,et al.  The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.

[550]  Timothy W. Evans,et al.  Glucose Control and Mortality in Critically Ill Patients , 2003 .

[551]  M. Laakso,et al.  Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. , 1996, Stroke.

[552]  L. Wallentin,et al.  A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. , 2002, Journal of the American College of Cardiology.

[553]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[554]  L. Hsu,et al.  Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis , 2002, Heart.

[555]  P. Nilsson,et al.  Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden , 2003, Journal of Human Hypertension.

[556]  T. Vos,et al.  Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. , 2003, American heart journal.

[557]  W. O’Neill Multivessel balloon angioplasty should be abandoned in diabetic patients! , 1998, Journal of the American College of Cardiology.

[558]  Yingxing Wu,et al.  Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[559]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[560]  Jerome Sacks,et al.  Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. , 2002, Journal of the American College of Cardiology.

[561]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[562]  M. Simoons,et al.  The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. , 2005, European heart journal.

[563]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[564]  G. Chatellier,et al.  The Framingham prediction rule is not valid in a European population of treated hypertensive patients , 2002, Journal of hypertension.

[565]  G. De Backer,et al.  Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[566]  H. Gerstein,et al.  Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients: A Systematic Overview , 2001, Stroke.

[567]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[568]  M. Hill,et al.  Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. , 1991, The Journal of clinical investigation.

[569]  N. Day,et al.  Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.

[570]  S. Dimmeler,et al.  Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. , 2001, The Journal of clinical investigation.

[571]  J. Kampine,et al.  Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. , 1987, Anesthesiology.

[572]  J. Tuomilehto,et al.  Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). , 1999, Diabetes care.

[573]  L. Gaal,et al.  Assessing the impact of complications on the costs of Type II diabetes , 2002, Diabetologia.

[574]  R. Frye,et al.  Coronary Bypass Graft Patency in Patients With Diabetes in the Bypass Angioplasty Revascularization Investigation (BARI) , 2002, Circulation.

[575]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology* , 2002 .

[576]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[577]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[578]  D. Rader,et al.  Lipases and HDL metabolism , 2002, Trends in Endocrinology & Metabolism.

[579]  I. Godsland,et al.  Loss of beta cell function as fasting glucose increases in the non-diabetic range , 2004, Diabetologia.

[580]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[581]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[582]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[583]  Hough Fs Type 2 Diabetes and the metabolic syndrome , 2007 .

[584]  J. Fuller,et al.  International variations in cardiovascular mortality associated with diabetes mellitus: the WHO Multinational Study of Vascular Disease in Diabetes. , 1996, Annals of medicine.

[585]  A. Whittemore Presidential address: a team for the 21st century: the vascular center. , 2000, Journal of vascular surgery.

[586]  E. Gilpin,et al.  Diabetic patients and beta-blockers after acute myocardial infarction. , 1990, European heart journal.

[587]  Claude Colette,et al.  Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). , 2003, Diabetes care.

[588]  P. Nilsson,et al.  Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. , 2002, Diabetes & metabolism.

[589]  Jaakko Tuomilehto,et al.  The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. , 2003, Diabetes care.

[590]  A. Gray,et al.  The Cost of Insulin‐dependent Diabetes Mellitus (IDDM) in England and Wales , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[591]  M W Knuiman,et al.  Prediction of coronary heart disease mortality in Busselton, Western Australia: an evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores. , 1997, Journal of epidemiology and community health.

[592]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[593]  Strokepreventioninatrialfibri The stroke prevention in atrial fibrillation III study: rationale, design, and patient features. , 1997, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[594]  D. Holmes,et al.  Lessons from the Pooled Outcome of the PAMI, ZWOLLE and Mayo Clinic Randomized Trials of Primary Angioplasty Versus Thrombolytic Therapy of Acute Myocardial Infarction. , 1998, The Journal of invasive cardiology.

[595]  E. Topol,et al.  The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. , 1999, Journal of the American College of Cardiology.

[596]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Journal of the American College of Cardiology.

[597]  G. Rose,et al.  RISK OF STROKE IN NON-RHEUMATIC ATRIAL FIBRILLATION , 1987, The Lancet.

[598]  M. Franz,et al.  The evidence for the effectiveness of medical nutrition therapy in diabetes management. , 2002, Diabetes care.

[599]  K. Narayan,et al.  Epidemiology and geography of type 2 diabetes mellitus , 2004 .

[600]  C. Bulpitt,et al.  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[601]  J. Shaw,et al.  A new IDF worldwide definition A new IDF worldwide definition of the metabolic syndrome: of the metabolic syndrome: the rationale and the results , 2005 .

[602]  James W. Anderson,et al.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). , 2002, Archives of internal medicine.

[603]  M. Hadamitzky,et al.  Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.

[604]  J. Sowers,et al.  Diabetes and cardiovascular disease. , 1999, Diabetes care.

[605]  J. Tuomilehto,et al.  Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. , 2004, Archives of internal medicine.

[606]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[607]  S. Yusuf,et al.  Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.

[608]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[609]  M. Laakso Perspectives in Diabetes Hyperglycemia and Cardiovascular Disease in me 2 Diabetes , 1999 .

[610]  J. Ottervanger,et al.  Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. , 1999, The New England journal of medicine.

[611]  M. Mclean,et al.  Insulin infusion therapy for myocardial infarction , 2006, Expert opinion on pharmacotherapy.

[612]  Pd redaction The prevention or delay of type 2 diabetes. , 2003, Caring : National Association for Home Care magazine.

[613]  L. Niskanen,et al.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. , 2001, Diabetes care.

[614]  AntonioCeriello,et al.  Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited , 2004 .

[615]  D. Bacquer,et al.  Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys , 2004, Diabetologia.

[616]  J. McKendry Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. , 1989, Canadian journal of public health = Revue canadienne de sante publique.

[617]  O. Schnell,et al.  A new look at the heart in diabetes mellitus: from ailing to failing , 2000, Diabetologia.

[618]  E. Braunwald Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.

[619]  A. Vinik,et al.  Platelet dysfunction in type 2 diabetes. , 2001, Diabetes care.

[620]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[621]  J. Segall Strategy of prevention: lessons from cardiovascular disease , 1981, British medical journal.

[622]  A. Folsom,et al.  Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Diabetes care.

[623]  C. Wolf‐peeters,et al.  Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients , 2005, The Lancet.

[624]  J. Bassand GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last. , 1994, European heart journal.

[625]  Jessie Venegas The Finnish Diabetes Prevention Study , 2008 .

[626]  K. Asplund,et al.  Diabetes as a risk factor for stroke. A population perspective , 1995, Diabetologia.

[627]  Å. Lernmark,et al.  Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. , 1993, Diabetes care.

[628]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[629]  F. Gao,et al.  Ischemia-Reperfusion : The Roles of PI 3-Kinase , Akt , and Endothelial Nitric Oxide Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial , 2002 .

[630]  N. Cox,et al.  Diabetes mellitus and early mortality from stroke , 1985, British medical journal.

[631]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[632]  D. Ewing,et al.  Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients , 1991, Diabetologia.

[633]  Dieter Mesotten,et al.  Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. , 2004, The Journal of clinical endocrinology and metabolism.

[634]  GerdAssmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002 .

[635]  J. Tuomilehto,et al.  Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? , 2003, Diabetes care.

[636]  N. Poulter,et al.  The anglo-scandinavian cardiac outcomes trial (ASCOT) , 1998 .

[637]  R. Califf,et al.  Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. , 1996, Journal of the American College of Cardiology.

[638]  J. Tuomilehto,et al.  Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland , 1998, Diabetologia.

[639]  Y. Seino,et al.  Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. , 2004, Diabetes research and clinical practice.

[640]  P. Tsao,et al.  Impaired Nitric Oxide Synthase Pathway in Diabetes Mellitus: Role of Asymmetric Dimethylarginine and Dimethylarginine Dimethylaminohydrolase , 2002, Circulation.

[641]  F. Zannad,et al.  Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. , 1999, Journal of the American College of Cardiology.

[642]  American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control * , 2004 .

[643]  T. Rea,et al.  Diabetes, glucose level, and risk of sudden cardiac death. , 2005, European heart journal.

[644]  A. Swai,et al.  Must diabetes be a fatal disease in Africa? Study of costs of treatment. , 1992, BMJ.

[645]  R. D'Agostino,et al.  Sudden coronary death in women. , 1998, American heart journal.

[646]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[647]  Matilde Peer education spotlight--meet Matilde. Interview by Amy Jo Harzke. , 1998, Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers.

[648]  R. Califf,et al.  Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. , 1997, Circulation.

[649]  G. Moneta,et al.  Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes , 2007 .

[650]  I. Piña Valsartan in acute myocardial infarction trial. , 2004, Current cardiology reports.

[651]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[652]  E. Eschwège,et al.  The cost of diabetes in France. , 1988, Health policy.

[653]  Curt D. Furberg,et al.  Incidence, Manifestations, and Predictors of Brain Infarcts Defined by Serial Cranial Magnetic Resonance Imaging in the Elderly: The Cardiovascular Health Study , 2002, Stroke.

[654]  J. Halter,et al.  Pathophysiology of Insulin Secretion in Non-insulin-dependent Diabetes Mellitus , 1984, Diabetes Care.

[655]  L. Rydén,et al.  Diabetes mellitus and congestive heart failure. Further knowledge needed. , 1999, European heart journal.

[656]  G. Thorgeirsson,et al.  Glucose tolerance and blood pressure in a population-based cohort study of males and females: the Reykjavik Study , 1995, Journal of hypertension.

[657]  L. Rydén,et al.  Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. , 1997, Cardiovascular research.

[658]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[659]  L. Rydén,et al.  Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the heart , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[660]  R. Schrier,et al.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.

[661]  A. Boulton,et al.  Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. , 2001, Diabetes care.

[662]  Alice Stanton,et al.  Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.

[663]  M. Lai,et al.  Direct costs-of-illness of patients with diabetes mellitus in Taiwan. , 2001, Diabetes research and clinical practice.

[664]  H. Keen,et al.  Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.

[665]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[666]  H. Yki-Järvinen Glucose toxicity. , 1992, Endocrine reviews.

[667]  H. L. Bleich,et al.  The Harvard Cooperative Stroke Registry , 1978, Neurology.

[668]  G A Colditz,et al.  The economic costs of non-insulin-dependent diabetes mellitus. , 1989, JAMA.

[669]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[670]  F. Game,et al.  Coronary heart disease risk assessment in diabetes mellitus–‐a comparison of PROCAM and Framingham risk assessment functions , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[671]  S. Juvela,et al.  Risk factors for multiple intracranial aneurysms. , 2000, Stroke.

[672]  J. Mehilli,et al.  Drug-eluting Stents in Diabetic Patients , 2006 .

[673]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[674]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[675]  P Ducimetière,et al.  Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. , 2003, European heart journal.

[676]  P. Whelton,et al.  Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. , 1997, JAMA.

[677]  A. Vinik,et al.  Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.

[678]  B. Davis,et al.  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.

[679]  L. Suzuki,et al.  Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. , 2001, Diabetes.

[680]  A. Rovlias,et al.  The influence of hyperglycemia on neurological outcome in patients with severe head injury. , 2000, Neurosurgery.

[681]  G. Pogátsa Metabolic energy metabolism in diabetes: therapeutic implications. , 2001, Coronary artery disease.

[682]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[683]  Vilmundur Gudnason,et al.  The association between glucose abnormalities and heart failure in the population-based Reykjavik study. , 2005, Diabetes care.

[684]  R. Frye,et al.  Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycemic agents. , 2004, American Journal of Cardiology.

[685]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[686]  E. Vartiainen,et al.  Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. , 1996, Stroke.

[687]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[688]  G. Pellegrini,et al.  Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[689]  M. Massi-Benedetti,et al.  The Costs of Type 2 Diabetes Mellitus in Italy , 2003, Treatments in endocrinology.

[690]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[691]  J. Tuomilehto,et al.  The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality , 2005, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[692]  J. Gardin,et al.  Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). , 1994, The American journal of cardiology.

[693]  O. Ljungqvist,et al.  Insulin resistance: a marker of surgical stress. , 1999, Current opinion in clinical nutrition and metabolic care.

[694]  S. Kaplan,et al.  Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. , 2005, Diabetes care.

[695]  S. Haffner,et al.  Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. , 2002, Diabetes care.

[696]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[697]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): Randomized, double-blind, placebo-controlled trial , 2004 .

[698]  Jaakko Tuomilehto,et al.  The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.

[699]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[700]  B. Rodrigues,et al.  Metabolic disturbances in diabetic cardiomyopathy , 1998, Molecular and Cellular Biochemistry.

[701]  R. Pratley,et al.  The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus , 2001, Diabetologia.

[702]  Farris K. Timimi,et al.  Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. , 1998, Circulation.

[703]  K. Channon,et al.  Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.

[704]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[705]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[706]  W. Kannel,et al.  Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.

[707]  B. Jönsson,et al.  Diabetes: the cost of illness in Sweden , 1998, Journal of internal medicine.

[708]  P. Vokonas,et al.  A comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. , 2002, American heart journal.

[709]  S. Yusuf,et al.  Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. , 2002, Diabetes care.

[710]  B. Lunenfeld Infertility throughout the ages. , 1995, Studies in profertility series.

[711]  H. Adams,et al.  Prevalence of diabetes mellitus among patients with subarachnoid hemorrhage. , 1984, Archives of neurology.

[712]  D. Brater,et al.  Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure , 1995, Clinical pharmacology and therapeutics.

[713]  X. Jouven,et al.  Diabetes as a risk factor for sudden death , 1999, The Lancet.

[714]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[715]  Paul M. Vanhoutte,et al.  The Endothelium: Modulator of Cardiovascular Function , 1990 .

[716]  X. Álvarez,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events , 2007 .

[717]  J. Colwell Aspirin Therapy in Diabetes , 1997, Diabetes Care.

[718]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[719]  W. Rand,et al.  Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. , 2000, American heart journal.

[720]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[721]  R. Hall,et al.  The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. , 2005, American heart journal.

[722]  J. Ottervanger,et al.  Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. , 1999, Diabetes care.

[723]  C. Loria,et al.  Subclinical states of glucose intolerance and risk of death in the U.S. , 2001, Diabetes care.

[724]  E. Barrett-Connor,et al.  Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. , 1991, JAMA.

[725]  Seppo Lehto,et al.  Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. , 2005, Diabetes care.

[726]  M. Hanefeld,et al.  Postprandial glucose regulation and diabetic complications. , 2004, Archives of internal medicine.

[727]  J. Tuomilehto,et al.  Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome , 2005, Diabetes & vascular disease research.

[728]  M. Laakso,et al.  Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. , 1996, Annals of medicine.

[729]  E. Antman,et al.  Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. , 2002, American heart journal.

[730]  L. Niskanen,et al.  Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. , 1996, Stroke.

[731]  C. van Weel,et al.  Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. , 2005, Diabetes care.

[732]  Shankuan Zhu,et al.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.

[733]  K. Swedberg,et al.  Expert consensus document on beta-adrenergic receptor blockers. , 2004, European heart journal.

[734]  R. Heethaar,et al.  Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study , 2000, Diabetologia.

[735]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[736]  C. Chiu,et al.  Salmonella typhimurium brain abscess in a six-month-old infant: a case report and review of the literature. , 1997, Changgeng yi xue za zhi.

[737]  S. Mudaliar,et al.  Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. , 2003, Diabetes care.

[738]  P A Wolf,et al.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.

[739]  F. Vancheri,et al.  Impaired glucose metabolism in patients with acute stroke and no previous diagnosis of diabetes mellitus. , 2005, QJM : monthly journal of the Association of Physicians.

[740]  G. V. Berghe,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[741]  P. Savage,et al.  Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria , 1999, The Lancet.

[742]  Scott K Aberegg,et al.  Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.

[743]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[744]  Y Li,et al.  Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. , 2001, American journal of physiology. Heart and circulatory physiology.

[745]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[746]  Ameet Bakhai,et al.  Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial , 2002, The Lancet.

[747]  J. Herman,et al.  Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. , 1989, Archives of internal medicine.

[748]  L Heinemann,et al.  Prevalence of renal artery stenosis in diabetes mellitus — an autopsy study , 1991, Journal of internal medicine.

[749]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.

[750]  S. Haffner,et al.  Are risk factors for conversion to NIDDM similar in high and low risk populations? , 1997, Diabetologia.

[751]  K. Feingold,et al.  Infection and inflammation-induced proatherogenic changes of lipoproteins. , 2000, The Journal of infectious diseases.

[752]  Deepak L. Bhatt,et al.  Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. , 2002, The American journal of cardiology.